GlassScriptPhysician profile
John S Featherston
NPI 1992919054
$4,857.91
in general payments reported to CMS, 2019-2025
32 companies · $582 in 2025
The $582 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $560 · 2021: $953 · 2022: $1,050 · 2023: $1,052 · 2024: $411 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $767.03 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $765.11 | 2021-2025 | |
| Glaxosmithkline, LLC. | $474.66 | 2020-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $300.11 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $299.10 | 2019-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $274.85 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $244.49 | 2020-2025 | Mounjaro, Kisunla, Zepbound |
| Pfizer INC. | $223.46 | 2019-2024 | |
| Amgen INC. | $222.17 | 2019-2025 | Repatha, Otezla, Prolia |
| Novo Nordisk INC | $191.75 | 2020-2025 | Ozempic, Rybelsus, Saxenda |
| Bayer Healthcare Pharmaceuticals INC. | $124.80 | 2023 | |
| Esperion Therapeutics, INC. | $124.15 | 2020-2022 | |
| Abbott Laboratories | $112.13 | 2021-2025 | Freestyle Libre 3, Cardiomems |
| Novartis Pharmaceuticals Corporation | $97.25 | 2019-2022 | |
| Genzyme Corporation | $90.67 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $83.07 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $67.19 | 2021 | |
| Eisai INC. | $45.96 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.42 | 2020-2023 | Jardiance |
| Astellas Pharma US INC | $39.91 | 2020 | |
| Jazz Pharmaceuticals INC. | $35.03 | 2021 | |
| Allergan, INC. | $33.54 | 2020 | |
| Antares Pharma, INC. | $30.80 | 2022-2023 | Xyosted, Nocdurna, Tlando |
| Genentech USA, INC. | $29.24 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $26.06 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $24.87 | 2022-2024 | Livalo |
| E.R. Squibb & Sons, L.L.C. | $15.69 | 2022 | |
| Currax Pharmaceuticals LLC | $15.63 | 2022 | |
| Harmony Biosciences LLC | $15.11 | 2023 | Wakix |
| Lundbeck LLC | $15.02 | 2024 | Rexulti |
| Horizon Therapeutics Plc | $14.58 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Featherston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.